Adaptive Biotechnologies slips as recent rally cools despite no clear new negative catalyst

Adaptive Biotechnologies Corporation (ADPT) is down 3.5% today. Here is some analysis on what might have caused this price movement.

Analysis: The catalyst is not fully clear, but the move appears consistent with profit-taking after a strong run in September rather than a fresh company-specific setback. Adaptive recently benefited from favorable updates tied to its clonoSEQ minimal residual disease testing business, so a modest pullback after that rally would not be unusual.

Details:

ADPT was trading at about $27.86 on October 1, 2026, down roughly 3.6% from the prior close, after opening near $29.00.

The stock had gained about 18.7% over the past month and nearly 78% year to date entering today, leaving shares vulnerable to short-term consolidation.

Adaptive highlighted on September 25 that a new international multiple myeloma cure definition uses sustained MRD negativity measured with highly sensitive testing, an update that supports the relevance of clonoSEQ.

Earlier, on September 17, the company announced updated NCCN multiple myeloma guidelines that strengthened MRD testing recommendations and specifically referenced clonoSEQ, which had helped sentiment and likely set a higher bar for follow-through buying.

Sources:

Adaptive Biotechnologies Investor Relations, Nasdaq, MarketBeat

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$ADPT Insider Trading Activity

$ADPT insiders have traded $ADPT stock on the open market 60 times in the past 6 months. Of those trades, 0 have been purchases and 60 have been sales.

Here’s a breakdown of recent trading of $ADPT stock by insiders over the last 6 months:

HARLAN S ROBINS (Chief Scientific Officer) has made 0 purchases and 7 sales selling 994,800 shares for an estimated $21,277,999.
CHAD M ROBINS (CEO and Chairman) has made 0 purchases and 6 sales selling 720,595 shares for an estimated $16,649,005.
FRANCIS LO (Chief People Officer) has made 0 purchases and 8 sales selling 379,315 shares for an estimated $8,819,959.
JULIE RUBINSTEIN (President and COO) has made 0 purchases and 21 sales selling 347,759 shares for an estimated $4,931,080.
SHARON BENZENO (Chief Commercial Ofc Imm Med) has made 0 purchases and 2 sales selling 165,802 shares for an estimated $3,503,509.
PETER M NEUPERT has made 0 purchases and 3 sales selling 124,690 shares for an estimated $3,135,850.
MICHELLE RENEE GRIFFIN sold 52,084 shares for an estimated $1,051,055
ROBERT HERSHBERG has made 0 purchases and 2 sales selling 30,664 shares for an estimated $748,208.
SUSAN BOBULSKY (Chief Commercial Officer, MRD) has made 0 purchases and 8 sales selling 31,981 shares for an estimated $659,655.
KATEY EINTERZ OWEN sold 9,615 shares for an estimated $249,990
KYLE PISKEL (Chief Financial Officer) sold 3,115 shares for an estimated $40,619

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$ADPT Hedge Fund Activity

We have seen 148 institutional investors add shares of $ADPT stock to their portfolio, and 121 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

D. E. SHAW & CO., INC. added 2,723,174 shares (+143.1%) to their portfolio in Q2 2026, for an estimated $58,412,082
WELLINGTON MANAGEMENT GROUP LLP added 2,053,944 shares (+53.2%) to their portfolio in Q2 2026, for an estimated $44,057,098
AMERIPRISE FINANCIAL INC removed 1,929,587 shares (-63.9%) from their portfolio in Q2 2026, for an estimated $41,389,641
BLACKROCK, INC. added 1,836,134 shares (+13.8%) to their portfolio in Q2 2026, for an estimated $39,385,074
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 1,776,523 shares (+56794.2%) to their portfolio in Q2 2026, for an estimated $38,106,418
PRINCIPAL FINANCIAL GROUP INC removed 1,666,058 shares (-97.7%) from their portfolio in Q2 2026, for an estimated $35,736,944
INVESCO LTD. removed 1,356,055 shares (-30.5%) from their portfolio in Q2 2026, for an estimated $29,087,379

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$ADPT Government Contracts

We have seen $465,930 of award payments to $ADPT over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

CLONO-SEQ TESTING.: $243,750
CLONOSEQ FDA-CLEARED IN VITRO DIAGNOSTIC (IVD) TESTING SERVICES: $128,700

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.

$ADPT Price Targets

Multiple analysts have issued price targets for $ADPT recently. We have seen 5 analysts offer price targets for $ADPT in the last 6 months, with a median target of $21.0.

Here are some recent targets:

Tejas Savant from Morgan Stanley set a target price of $20.0 on 07/09/2026
Subbu Nambi from Guggenheim set a target price of $22.0 on 06/29/2026
Mark Massaro from BTIG set a target price of $22.0 on 06/17/2026
Sebastian Sandler from JP Morgan set a target price of $19.0 on 05/06/2026
Dan Brennan from TD Cowen set a target price of $21.0 on 05/06/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.